LAS VEGAS, Jan. 22, 2014 /PRNewswire/ -- BioAdaptives, Inc. has announced that its Form S-1 filing has become effective as of January 10, 2014. The company has engaged a FINRA broker dealer to submit its 15c211 filing with FINRA and expects to obtain a ticker symbol. Additionally, the company will also be seeking DTC eligibility shortly with The Depository Trust & Clearing Corporation (DTCC). 2,000,000 shares of BioAdaptives, Inc. stock, as noted within the Form S-1 filing, will be distributed to shareholders of HEMP, Inc. (Pink Sheets: HEMP).
"Today's announcement is an important milestone in our company's achievement as we begin to develop and execute our plans as a publicly-traded company in the coming weeks and months. As we expand our corporate footprint, we are also eager to develop and bring high quality nutraceuticals to market for health and wellness conscious consumers," commented Gerald Epling, the President and Chief Executive Officer of BioAdaptives, Inc.
ABOUT BIOADAPTIVES, INC.
BioAdaptives, Inc., is a fully-reporting public company engaged in research, development, and educational activities. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages. Our base of intellectual property and products, which are patent pending solutions in the form of devices and nutraceuticals, are designed to aid in cognition, focus, fatigue reduction, increased testosterone, improved overall emotional and physical wellness, healing, and anti-aging.
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward-looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding dietary, nutritional supplements, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types, (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the dietary nutritional supplement industry or, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control. Copies of our SEC reports are available upon request from our corporate office or may be obtained at the SEC's website (www.sec.gov).
SOURCE BioAdaptives, Inc.